BMR offers a variety of antibodies that are exhaustively produced by using "Concomitant Immunization with Multiple Antigens", which is BMR's proprietary method of producing monoclonal antibodies. We are currently producing monoclonal antibodies that target mainly DNA binding proteins in the nucleus.
| Genome-based drug discovery |
|
As genome research has progressed, technological innovations for genetic analysis have been developed, enabling us to accumulate information at an accelerated pace on genetic sequences, polymorphism, and gene expression. It is obvious that human genome research will have an immeasurable influence on medical science and medical services in the 21st Century.
The progress of genome research has enabled not individual genetic research, but networked genetic research that can systematically analyze a vast amount of information on genetic polymorphisms ranging from several tens of thousands to several hundred thousand types, and on gene expressions ranging from several thousand to several tens of thousands of types.
As a result, analyses of differences in the quality and quantity of a vast amount (from a few dozen to several tens of thousands) of genes and genetic products have multilaterally revealed the molecular mechanisms of diseases and their pathologic conditions. BMR positively provides customers with support for drug discovery based on a vast amount of genomic information.
The importance of bioinformatics in genome-based drug discovery has markedly increased because of a dramatic increase in the volume of computer analysis and data management needed for the discovery. In this bioinformatics field, we will be able to provide a wide range of support services for genome-based drug discovery in the future, directly meeting the needs of pharmaceutical companies.
|
